NCT02566564 is a Phase 1 clinical trial of Lopain in Osteoarthritis, Knee, sponsored by Grünenthal GmbH.

Who is sponsoring NCT02566564?

NCT02566564 is sponsored by Grünenthal GmbH.

What drugs are being tested in NCT02566564?

Interventions in NCT02566564: Lopain.

What condition does NCT02566564 study?

NCT02566564 studies Osteoarthritis, Knee.

Is NCT02566564 still recruiting?

NCT02566564 is currently completed. Last updated 12 July 2021.

Last reviewed 2021-07-12 · How we verify

NCT02566564

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open Label, Single Dose, Dose-escalating Phase I/IIa Study to Determine the Safety and Clinical Effects of Intra-articular Injections of Lopain (MTX-071) in Patients With Chronic Osteoarthritic Knee Joint Pain

Completed Phase 1 Last updated 12 July 2021

What this trial tests

Phase 1 trial testing Lopain in Osteoarthritis, Knee in 23 participants. Completed in 1 June 2017.

Timeline

1 April 2016

Primary endpoint
1 June 2017

1 June 2017

Quick facts

Lead sponsor	Grünenthal GmbH
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	23
Start date	1 April 2016
Primary completion	1 June 2017
Estimated completion	1 June 2017
Sites	1 location across Belgium

Drugs / interventions tested

Lopain — full drug profile →

Conditions studied

Osteoarthritis, Knee — all drugs for Osteoarthritis, Knee →

Sponsor

Grünenthal GmbH — full company profile →

Who can join

Adults 40 to 70, any sex, with Osteoarthritis, Knee. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Intensity and severity of AES/SAEs potentially causally related with the study medication
Time frame: up to 6 months
overall and per dose level (descriptive statistics) incidence, intensity and severity of AES/SAEs potentially causally related with the study medication

Sponsor's own description

Phase I/IIa study to determine the safety and clinical effects of intra-articular injections of MTX-071 (Lopain) in patients with chronic osteoarthritic knee-joint pain.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

TRPV Channels in Osteoarthritis: A Comprehensive Review.
Chen C, Yang F, Chen R, Yang C, et al · · 2024 · cited 16× · PMID 38540712 · DOI 10.3390/biom14030292
Pharmaceutical therapeutics for articular regeneration and restoration: state-of-the-art technology for screening small molecular drugs.
Chen Y, Sun H, Yao X, Yu Y, et al · · 2021 · cited 9× · PMID 34783870 · DOI 10.1007/s00018-021-03983-8
TRPV1 Receptor Modulators: Emerging Therapies for Neuropathic, Osteoarthritic, and Perioperative Pain.
Tsai EH, Gan TJ. · · 2026 · PMID 41722000 · DOI 10.1007/s40263-026-01272-1

Verify or expand the search:

Other recruiting trials for Osteoarthritis, Knee

Currently open trials in the same condition.

NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT06488144 — Rehabilitation for Arthritis of The Knee: mainTaining Improvement for Veterans · Phase 3 · recruiting
NCT07386561 — Virtual Reality Therapy and Non-Sleep Deep Rest Relaxation After Joint Arthroplasty · NA · active not recruiting
NCT07514598 — Effect of J-Shaped Incision After Total Knee Arthroplasty (J-TKA) · NA · active not recruiting
NCT07058623 — Nurse-Led Telehealth vs In-Person Follow-Up After Total Knee Replacement · NA · recruiting

Other Grünenthal GmbH trials

Trials by the same sponsor.

NCT07479745 — Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]GRT6019 · Phase 1 · recruiting
NCT07289776 — A First-in-human Trial of GRT7041 in Healthy Participants · Phase 1 · recruiting
NCT07317063 — A Trial to Investigate Safety and Pharmacokinetics of GRT6019, Including Food Effect, in Healthy Male Participants · Phase 1 · completed
NCT05449132 — Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the · Phase 3 · completed
NCT05377489 — Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02566564 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Grünenthal GmbH
Last refreshed: 12 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02566564.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing